A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen

• Published in: Journal of virological methods Vol. 157; no. 1; pp. 8 - 14
• Main Authors: Morota, Kaori, Fujinami, Ryo, Kinukawa, Hideki, Machida, Taiji, Ohno, Kenichi, Saegusa, Haruhisa, Takeda, Katsumichi
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.04.2009; Elsevier
• Subjects: Antigens, Viral - blood; Automation - methods; Biological and medical sciences; Chemiluminescent immunoassay; Fundamental and applied biological sciences. Psychology; HCV core antigen; Hepacivirus - immunology; Hepatitis C; Hepatitis C virus; Humans; Immunoassay - methods; Luminescent Measurements - methods; Microbiology; Microspheres; Plasma - chemistry; RNA, Viral - blood; Sensitivity and Specificity; Serum - chemistry; Techniques used in virology; Viral Core Proteins - blood; Virology; Hepatitis C; Chemiluminescent immunoassay; HCV core antigen; Microbiology; Method; Virology; Infection; Virus; Antigen; Viral disease; Flaviviridae; Hepatitis C virus; Hepacivirus; Quantitative analysis; Viral hepatitis C
• ISSN: 0166-0934; 1879-0984
• DOI: 10.1016/j.jviromet.2008.12.009

A new sensitive and automated chemiluminescent assay was developed for the quantitative determination of hepatitis C virus (HCV) core antigen (Ag) in human sera or plasma: the Abbott ARCHITECT ® HCV Ag test. The assay sensitivity was determined by testing 10 commercial HCV seroconversion panels. Without exception, a positive result for HCV core Ag was observed before anti-HCV detection, resulting in an average reduction in the period between exposure and detection of 35.8 days. Both HCV core Ag and HCV RNA were detected in the panels at the same time, indicating equivalent sensitivity and detectability. A total of 197 HCV specimens comprising genotypes 1a, 1b, 2a, 2b, 3a, 3k, 4a, 5a and 6a were evaluated. Among these, 196 (99.5%), 191 (97%) and 193 (98%) were reactive using the HCV Ag, the immunoradiometric HCV Ag and the Amplicor HCV Monitor 2 assays, respectively. A comparison with the Amplicor HCV Monitor 2 showed a correlation coefficient ( r) of 0.74. The specificity of the assay was established at 99.8% by testing 5403 specimens from US volunteer blood donors, hospitalized patients and individuals with medical conditions unrelated to HCV infection, in addition to specimens containing potentially interfering substances.